Clinical trials: Hyperparathyroidism; Secondary, Renal
Chronic Renal Insufficiency, Renal Osteodystrophy
Clinical Observation on Bone Metabolism Induced by Chronic Renal Insufficiency
Patients with chronic renal insufficiency usually develop secondary osteoporosis or bone loss, which is called renal osteodystrophy.
- Trial name
- NCT02147782
- Where
- 4 sites in China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Shanghai University of Traditional Chinese Medicine
Renal Failure, Kidney Donors
BOne Dysfunction in Donor NEphrectomieS
Most dialysis patients die from vascular disease, which is statistically associated with changes related to chronic kidney disease associated mineral bone disorder (CKD-MBD)3-9.
- Trial name
- BONES (NCT04674397)
- Testing
- Radioisotope GFR test
- Where
- United Kingdom
- Volunteers
- 34 people
- Sponsor
- Manchester University NHS Foundation Trust
Chronic Kidney Disease Mineral and Bone Disorder, Chronic Kidney Disease (CKD)
The CPH-MBD Cohort
Persons with chronic kidney disease (CKD) have a 3-fold increased risk of bone fracture and a 10-fold increased risk of cardiovascular disease than the general population.
- Conditions
- Chronic Kidney Disease Mineral and Bone Disorder, Chronic Kidney Disease (CKD), Bone Markers
- Trial name
- NCT07193056
- Where
- Denmark
- Volunteers
- 1,000 people
- Sponsor
- Herlev Hospital
Chronic Kidney Disease, Hyperparathyroidism, Secondary
Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency
This study will evaluate the efficacy of CTAP101 Capsules versus placebo in reducing intact parathyroid hormone (iPTH) by at least 30% from pretreatment baseline; safety and tolerability of CTAP101 will also be evaluated
- Conditions
- Chronic Kidney Disease, Hyperparathyroidism, Secondary, Vitamin D Deficiency
- Trial name
- NCT01651000
- Testing
- CTAP101 30 μg capsules, Sugar pill to CTAP101 30 μg capsules
- Where
- United States
- Volunteers
- 213 people
- Sponsor
- OPKO IP Holdings II, Inc.
Chronic Kidney Disease-Mineral and Bone Disorder
Relationship Between Serum 1,25-dihydroxy Vitamin D and Markers of Bone Metabolism in Renal Dysfunction Patients
This cross-sectional study was conducted, including those subjects tested for 1,25(OH)2D during Jan 2015-Dec 2021. Estimated glomerular filtration rate (eGFR) was calculated and subjects were classified into chronic kidney…
- Trial name
- NCT05399251
- Volunteers
- 1,553 people
- Sponsor
- Aga Khan University Hospital, Pakistan
Chronic Kidney Disease stage3, Chronic Kidney Disease stage4
Phase 3 Safety and Efficacy Study of CTAP101 Extended-release Capsules in Children With Secondary Hyperparathyroidism
This is a phase 3, multi-center, randomized, double-blind, placebo-controlled study in children with stage 3-4 chronic kidney disease (CKD), secondary hyperparathyroidism (SHPT) and vitamin D insufficiency.
- Conditions
- Chronic Kidney Disease stage3, Chronic Kidney Disease stage4, Vitamin d Deficiency, Secondary Hyperparathyroidism
- Trial name
- NCT05543928
- Testing
- CTAP101
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- OPKO Health, Inc.
ESRD
Pharmacoepidemiological Study of Secondary Hyperparathyroidism in Lorraine
The pharmacoepidemiological EPHEYL (Étude PHarmacoÉpidémiologique de l'hYperparathyroïdie secondaire en Lorraine) study is a 2-year, open-cohort, prospective, observational study on incident SHPT, i.e.
- Trial name
- EPHEYL (NCT02888639)
- Volunteers
- 305 people
- Sponsor
- Central Hospital, Nancy, France
Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) on Hemodialysis
Study of MT1013 Injection for the Treatment of Secondary Hyperparathyroidism (SHPT) Patients With Chronic Kidney Disease Undergoing Maintenance Dialysis
This is a multi-center, open, single-arm phase IIb clinical study comprising 2 parts, which Part A will enroll about 110 subjects, and Part B will enroll about 190 subjects to investigate long-term efficacy and safety of MT1013…
- Trial name
- NCT06976177
- Testing
- MT1013
- Where
- China
- Volunteers
- 310 people
- Sponsor
- Shaanxi Micot Pharmaceutical Technology Co., Ltd.
CKD-MBD - Chronic Kidney Disease Mineral and Bone Disorder, Secondary Hyperparathyroidism
The Longitudinal PTH-Study
The main study aim is to quantify the agreement between the analytical results provided by two third generation and two second generation Parathyroid hormone (PTH) assays.
- Conditions
- CKD-MBD - Chronic Kidney Disease Mineral and Bone Disorder, Secondary Hyperparathyroidism, Kidney Replacement
- Trial name
- NCT03464149
- Testing
- One armed study, blood from each patient is analysed by four assays ( two 3rd generation and two 2nd generation assays)
- Where
- Austria
- Volunteers
- 132 people
- Sponsor
- Medical University of Vienna
End Stage Renal Disease (ESRD), CKD 5D, Hemodialysis
Activated Charcoal Use in Chronic Kidney Disease Patients
Hyperphosphatemia management is initially based on restricting dietary phosphorus intake. Hyperphosphatemia is almost always seen in patients on dialysis and may contribute to progressive vascular calcification.
- Conditions
- End Stage Renal Disease (ESRD), CKD 5D, Hemodialysis, CKD-MBD - Chronic Kidney Disease Mineral and Bone Disorder
- Trial name
- NCT06906874
- Testing
- Activated Charcoal, Phosphate Binders
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Mansoura University
CKD Stage 3, CKD Stage 4
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability Evaluation of CTAP101 Extended-release Capsules in Pediatric Participants
The goal of this clinical trial is to evaluate safety, tolerability, and how CTAP101 Capsules work to treat Pediatric Participants with Secondary Hyperparathyroidism, Stage 3 or 4 Chronic Kidney Disease and Vitamin D…
- Conditions
- CKD Stage 3, CKD Stage 4, Secondary Hyperparathyroidism, VDI
- Trial name
- NCT07494045
- Testing
- CTAP101
- Where
- 5 sites in United States
- Volunteers
- 40 people
- Sponsor
- OPKO Health, Inc.
Secondary Hyperparathyroidism, End Stage Renal Disease
A Study to Follow-up Patients With End Stage Renal Disease Undergoing Hemodialysis, Receiving Selective Vitamin D Receptor Activator's for Prevention and Treatment of Secondary Hyperparathyroidism
The aim of this post-marketing observational study is to obtain further data on the long term use, safety and efficacy of selective Vitamin D Receptor Activator's as it is prescribed in the normal clinical setting and according…
- Trial name
- NCT01149291
- Where
- 22 sites in Turkey (Türkiye)
- Volunteers
- 511 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Kidney Tansplant, Secondary Hyperparathyroidism
Post Transplant Study
Retrospective chart review to gather information on Sensipar patterns of use and effects on biochemical parameters in renal transplant recipients
- Conditions
- Kidney Tansplant, Secondary Hyperparathyroidism, Hyperparathyroidism
- Trial name
- NCT00395902
- Testing
- Sensipar after Post Transplant
- Volunteers
- 50 people
- Sponsor
- Amgen
Secondary Hyperparathyroidism, End-stage Kidney Disease
The Effect of Increasing Dialysate Calcium on T50 in Subjects With Secondary Hyperparathyroidism and ESKD
Patients with end-stage kidney disease (ESKD) have an increased risk of cardiovascular mortality. High parathyroid hormone (PTH) from secondary hyperparathyroidism leads to increased efflux of phosphate and calcium from bone…
- Trial name
- CaT50HD (NCT06398002)
- Testing
- Dialysate calcium 1.50 mmol/L
- Volunteers
- 48 people
- Sponsor
- Iain Bressendorff
Hemodialysis Complication, Shoulder Joint Disorder
The Effect of Baduanjin on Shoulder Function in Maintenance Hemodialysis Patients
The aim of this study is to examine the effect of 18-month Baduanjin exercise on shoulder joint function in maintenance hemodialysis (MHD) patients.
- Conditions
- Hemodialysis Complication, Shoulder Joint Disorder, CKD-MBD
- Trial name
- NCT06314321
- Testing
- Baduanjin exercise
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Affiliated Hospital of Nantong University
Renal Osteodystrophy
Systematic Study of Parameters of Chronic Kidney Disease Mineral and Bone Disorder (CKD-MBD)
Bone and mineral disease is a key problem in patients with kidney disease. The available clinical parameters are non-specific, unproven for the assessment of the bone metabolism and do not reflect the complexity and diversity of…
- Trial name
- BoneX (NCT02556216)
- Where
- Germany
- Volunteers
- 100 people
- Sponsor
- Hannover Medical School
Chronic Kidney Disease, Renal Osteodystrophy
Serum Sclerostin Levels, Cardiovascular Parameters and Carpal Tunnel Syndrome in Maintenance Hemodialysis Patients
Sclerostin, the product of the SOST gene, located on chromosome 17, locus q11.2 in humans, was originally believed to be a non-classical Bone morphogenetic protein (BMP) antagonist.Sclerostin was recently identified as a…
- Conditions
- Chronic Kidney Disease, Renal Osteodystrophy, Left Ventricular Hypertrophy
- Trial name
- NCT01382966
- Where
- Turkey (Türkiye)
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- RFM Renal Treatment Services
Secondary Hyperparathyroidism, Renal Insufficiency, Chronic
Effectiveness and Safety of IV Zemplar in Patients on Hemodialysis and With Secondary Hyperparathyroidism Using iPTH/100 as Initial Dose
The purpose of this study is to observe the effectiveness and safety of the use of a low initial dose regime (iPTH/100) in chronic kidney disease patients with secondary hyperparathyroidism (PTH>300pg/mL) and that require…
- Conditions
- Secondary Hyperparathyroidism, Renal Insufficiency, Chronic, Parathyroid Hormone, Hemodialysis
- Trial name
- NCT00891813
- Testing
- Zemplar (paricalcitol)
- Where
- 3 sites in Peru
- Volunteers
- 100 people
- Sponsor
- Abbott
Chronic Kidney Disease
Chronic Kidney Disease and Bone - Correlation Between 18F-PET-TT Imaging and Histomorphometry of Bone in CKD Patients
Chronic kidney disease (CKD) is an increasing public health problem and the number of patient with chronic kidney disease is increasing worldwide.
- Trial name
- CKD-Bone (NCT02967042)
- Testing
- 18F-PET-TT
- Where
- Finland
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Turku University Hospital
Secondary Hyperparathyroidism, Hypercalcemia
Cinacalcet to Treat Hypercalcemia in Renal Transplant Recipients
Secondary hyperparathyroidism can persist following successful renal transplantation and can cause high blood calcium, kidney dysfunction or failure and excessive bone loss among other problems.
- Trial name
- NCT00415584
- Testing
- Cinacalcet HCl
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Montefiore Medical Center